In a report released yesterday, Tim Anderson from Bank of America Securities maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: Oatly Group AB (OTLY) 155.98% +2.55, Trevi ...

Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) released topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN ...

NASDAQ MLYS opened at $14.30 on Wednesday. The stock’s fifty day moving average price is $10.35 and its 200-day moving average price is $11.90. Mineralys Therapeutics, Inc. has a 12 month low of ...

NASDAQ:MLYS opened at $14.96 on Monday. The firm has a market capitalization of $745.55 million, a P/E ratio of -4.11 and a beta of 1.50. The business has a 50 day simple moving average of $10.31 ...

Mineralys Therapeutics said on Monday its lead drug significantly lowered blood pressure in patients with difficult-to-treat hypertension in late- and mid-stage trials.

Mineralys Therapeutics (Nasdaq: MLYS) saw its stock rise by over 40% after reporting positive top-line results from two ...

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...

A Radnor biopharma firm saw its stock price skyrocket after the company posted positive late-stage clinical trial results for ...

The company anticipates initiating the trial in the first quarter of 2025. Price Action: MLYS stock is up 65.70% at $17.43 at the last check Monday.

Mineralys Therapeutics (MYLS) priced an underwritten public offering of ~12.96M shares at a public offering price of $13.50 per share. The aggregate gross proceeds are expected to be ~$175M.